Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: Dr Kastrati and colleagues1 reported that among patients with acute myocardial
infarction who were referred for percutaneous interventions, early administration
of reteplase plus abciximab does not lead to a reduction of infarct size compared
with abciximab alone. However, because the trial, which was conducted in Germany,
used intravenous 500-mg aspirin as part of the initial treatment, the results
may not be applicable to patients in the United States, where aspirin is only
available in an oral form.
Busti AJ, Marshall KS, Hooper JS. Reteplase in Acute Myocardial Infarction. JAMA. 2004;291(20):2429-2430. doi:10.1001/jama.291.20.2429-c